Philips announces first patient treated with its new real-time 3D intracardiac echocardiography catheter – VeriSight Pro
01 July 2021 - 11:00PM
July 01, 2021
- FDA 510k-cleared real-time 3D intracardiac echocardiography
(ICE) catheter has potential to improve standard of care for
structural heart disease and electrophysiology procedures
- Reduced need for general anesthesia accelerates workflows,
increases efficiency, and broadens treatment options
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the first minimally-invasive heart procedure using its
new real-time 3D intracardiac echocardiography (ICE) catheter. The
Left Atrial Appendage Occlusion (LAAO) procedure was carried out by
Mohamad Adnan Alkhouli, M.D., at Mayo Clinic (Minnesota, U.S.).
Used together with Philips Premium Cardiology Ultrasound System
(EPIQ CVx), the real-time 3D Philips Intracardiac Echocardiography
Catheter – VeriSight Pro – offers superior 2D and 3D live image
guidance for a wide range of procedures in structural heart disease
and electrophysiology, allowing interventionalists to navigate
procedures with ease, provide superior care, and optimize cath lab
performance.
Live ultrasound imaging during structural heart disease and
electrophysiology procedures typically relies on transesophageal
echocardiography (TEE) imaging, in which an ultrasound probe is
passed down the patient’s throat and into their esophagus, until it
lies next to the heart. TEE requires the patient to be sedated or
given general anesthesia, lengthening preparation, procedure, and
recovery times and carrying a degree of risk. Philips’ ICE catheter
VeriSight Pro uses the same ultrasound technology, miniaturized to
fit on the tip of a 1.98mm diameter (9 French) catheter so that it
can be navigated to the patient’s heart via their vasculature - the
same route used to introduce other catheters during
minimally-invasive cardiac surgery. General anesthesia is typically
not required, reducing patient risk, and opening up procedures to
patients who are not good anesthesia candidates.
“Securing the best-possible live images enables interventional
cardiologists and electrophysiologists to boost procedure
confidence and deliver optimum outcomes for more patients,” said
Chris Landon, Senior Vice President and General Manager Image
Guided Therapy Devices at Philips. “The exceptional 2D and 3D
imaging capabilities of Philips Intracardiac Echocardiology
Catheter – VeriSight Pro – make it a superb choice for image
guidance in interventional procedures, reducing reliance on general
anesthesia and the logistical hurdles that go with it.”
For interventional cardiologists, VeriSight Pro delivers a good
alternative high quality 3D live image to TEE, including 3D Volume
and Color Flow imaging. Based on Philips’ innovative xMATRIX 3D
ultrasound transducer technology, Verisight Pro can provide a 90 by
90 degree 3D field of view as well as allowing physicians to view
two scan planes simultaneously - for example, the long and short
axes of the left atrial appendage (LAA) to select the appropriately
sized device for LAA closure. VeriSight Pro provides superior 2D
ICE imaging, as well as the ability to access new views more
easily. Interventionalists can digitally change the scan angle to
capture views without manually repositioning the ultrasound tip, a
unique feature of this ICE catheter.
Philips Intracardiac Echocardiology Catheter – VeriSight Pro –
is designed to be used with Philips Premium Cardiology Ultrasound
System (EPIQ CVx). Philips offers integrated solutions for the
treatment of Structural Heart Disease, combining interventional
X-ray, 3D ultrasound and related interventional tools that are
designed to enable confident navigation and positioning of devices
to optimize outcomes while reducing procedure time.
Philips Intracardiac Echocardiology Catheter – VeriSight Pro –
is available on a limited basis in the U.S.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel.: +31 631 639
916E-mail: mark.groves@philips.com
Fabienne van der FeerPhilips Image Guided TherapyTel: + 31 622
698 001E-mail: fabienne.van.der.feer@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health
technology company focused on improving people's health and
well-being, and enabling better outcomes across the health
continuum – from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2020 sales of EUR 17.3 billion and
employs approximately 77,000 employees with sales and services in
more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
- Real-time 3D Philips Intracardiac Echocardiography Catheter –
Verisight Pro
- Philips Intracardiac Echocardiography Catheter – Verisight Pro
– product only
- Philips Intracardiac Echocardiography Catheter – Verisight Pro
– product in hand
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Apr 2023 to Apr 2024